FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2497788249> ?p ?o ?g. }

• W2497788249 endingPage "1726" @default.
• W2497788249 startingPage "1726" @default.
• W2497788249 abstract "Abstract Background: MCL is B-cell neoplasm diagnosed predominantly among older men. (R)CHOP-like regimens demonstrated high response rate, but the event-free survival (EFS) and overall survival (OS) are disappointingly short - 16-20 months and 3-4 years, respectively. An addition of high-dose AraC (12 g/m2) to the upfront therapy and autoSCT have significantly improved outcomes but remain feasible largely for younger and medically fit patients. Based on the activity and good tolerance of gemcitabine-oxaliplatin combinations in relapsed and refractory MCL patients, we developed an alternative first-line regimen for patients who are not candidates for R-HD-MTX-AraC (R-HMA). We presented an initial data of our pilot protocol at ASH 2012 (#2043). According to the protocol patients who had renal insufficiency and/or experience prohibitive toxicity following the first course of R-EPOCH, were assigned to receive R-EPOCH/R-GIDIOX regimen, while others were treated with R-EPOCH/R-HMA regimen. Both arms received consolidative autoSCT followed by R-maintenance. Aim: Assess toxicity and efficacy of R-DA-EPOCH/R-HMA and R-DA-EPOCH/R-GIDIOX in untreated MCL patients eligible for autoSCT. Patients and Methods: 47 untreated MCL patients from 6 centers were enrolled in prospective study between May 2008 - Sep. 2013; stage II-IV; ECOG 0-3; median age 55 years (29-64); M/F 76%/24%; MIPIb: 28% low, 33% intermediate and 39% high risk. Following 1st R-EPOCH patients were assigned to receive either R-DA-EPOCH/R-HMA or R-DA-EPOCH/R-GIDIOX regimen. In the absence of hematological toxicity gr. 4, severe infections and renal failure patients received R-HMA (R 375 mg/m2 d1, MTX 1000 mg/m2/24 hours d 2, AraC 3000 mg/m2 q 12 hrs d 3-4). Patients who experienced at least one of the complications above received R-GIDIOX (R 375 mg/m2 d 1, gemcitabine 800 mg/m2 d 2 and 5, oxaliplatin 120 mg/m2 d 3, irinotecan 100 mg/m2 d 4, dexamethasone 10 mg/m2 IV d 2-6, ifosfamide 1000 mg/m2 d 2-6). Subsequently these courses were alternating with R-DA-EPOCH in each arm of the protocol. Patients who achieved CR after the first cycle (2 courses), received additional 2 cycles, (for a total 6 courses). Patients without CR after 2 cycles of therapy received 2 more cycles, for total of 8 courses, unless they progressed on therapy. Those patients who achieved PR/CR/CRu underwent autoSCT (BEAM-R). Response the therapy was assessed by Cheson's criteria (2007). Patients with residual PET+ tumor after autoSCT were consolidated with local radiotherapy. Post-transplant R- maintenance was administered for 3 years (R-375 mg/m2 every 3 months). Patients were analyzed on an intent-to-treat basis. Results: 29/47 patients were treated on R-HMA arm (Arm1) (median 51years; MIPIb: 35,7% low, 28,6% intermediate and 35,7% high risk) and 18/47 patients were on R-GIDIOX arm (Arm2) (median 60 years; MIPIb: 16,7% low, 38,9% intermediate and 44,4% high risk). There was 1/29 induction death after first R-HMA course (acute renal failure and septic shock). 1 of 18 patients had disease progression before autoSCT in Arm2. 28/29 patients from Arm1 achieved CR/CRu (96,6%). In Arm 2 OR and CR/CRu rates were 94,4% (17/18) and 77,8% (14/18), respectively. Main non-hematological toxicity of R-GIDIOX was asymptomatic elevation of transaminases (gr. 1-2 and 3-4 in 65,5% and 6,9% of courses respectively), while leukopenia gr. 4 occurred in 74,1% of courses (median 5 days, range 1-13), thrombocytopenia gr. 4 -39,7% courses. 45/47 patients underwent autoSCT: 28/29 in Arm1 and 17/18 in Arm2. The sources of stem cells were PBSC in 39/45 patients (86,7%) and BM in 6/45 (13,3%) patients with PBSC collection failure following R-HMA (3/28) or R-GIDIOX (3/17). With median follow-up of 31 months (range 11-76), the estimated 4-year OS and EFS remain identical in both groups: 78% (SE 12%) and 72% (SE 18%), respectively. Conclusions: Combination of R-DA-EPOCH/R-GIDIOX followed autoSCT and R-maintenance is well tolerated and produces EFS/OS similar to those seen with more toxic regimen utilizing R-HD-MTX-AraC. Equal outcomes were observed despite higher proportion of high risk patients treated with non-HD-AraC regimen. We conclude that R-GIDIOX can be an alternative component of induction regimen for those patient with MCL who are not candidates for intensification with high-dose AraC and MTX. Figure 1 Figure 1. Figure 2 Figure 2. Disclosures No relevant conflicts of interest to declare." @default.
• W2497788249 created "2016-08-23" @default.
• W2497788249 creator A5006140546 @default.
• W2497788249 creator A5015768274 @default.
• W2497788249 creator A5017815439 @default.
• W2497788249 creator A5025177149 @default.
• W2497788249 creator A5036770808 @default.
• W2497788249 creator A5043454332 @default.
• W2497788249 creator A5044776670 @default.
• W2497788249 creator A5045124021 @default.
• W2497788249 creator A5046804186 @default.
• W2497788249 creator A5063099776 @default.
• W2497788249 creator A5077089081 @default.
• W2497788249 creator A5082766154 @default.
• W2497788249 date "2014-12-06" @default.
• W2497788249 modified "2023-10-18" @default.
• W2497788249 title "Less Toxic Gemcitabine-Oxaliplatin Based Induction Regimen (R-GIDIOX) Prior to Autologous SCT Produces Outcomes Similar to High-Dose Cytarabine Containing Intensive Induction Regimen in Mantle Cell Lymphoma – a Follow up Report of the Multicenter Study" @default.
• W2497788249 doi "https://doi.org/10.1182/blood.v124.21.1726.1726" @default.
• W2497788249 hasPublicationYear "2014" @default.
• W2497788249 type Work @default.
• W2497788249 sameAs 2497788249 @default.
• W2497788249 citedByCount "1" @default.
• W2497788249 countsByYear W24977882492019 @default.
• W2497788249 crossrefType "journal-article" @default.
• W2497788249 hasAuthorship W2497788249A5006140546 @default.
• W2497788249 hasAuthorship W2497788249A5015768274 @default.
• W2497788249 hasAuthorship W2497788249A5017815439 @default.
• W2497788249 hasAuthorship W2497788249A5025177149 @default.
• W2497788249 hasAuthorship W2497788249A5036770808 @default.
• W2497788249 hasAuthorship W2497788249A5043454332 @default.
• W2497788249 hasAuthorship W2497788249A5044776670 @default.
• W2497788249 hasAuthorship W2497788249A5045124021 @default.
• W2497788249 hasAuthorship W2497788249A5046804186 @default.
• W2497788249 hasAuthorship W2497788249A5063099776 @default.
• W2497788249 hasAuthorship W2497788249A5077089081 @default.
• W2497788249 hasAuthorship W2497788249A5082766154 @default.
• W2497788249 hasConcept C121332964 @default.
• W2497788249 hasConcept C121608353 @default.
• W2497788249 hasConcept C126322002 @default.
• W2497788249 hasConcept C1276947 @default.
• W2497788249 hasConcept C141071460 @default.
• W2497788249 hasConcept C150846664 @default.
• W2497788249 hasConcept C2776694085 @default.
• W2497788249 hasConcept C2777525834 @default.
• W2497788249 hasConcept C2778041864 @default.
• W2497788249 hasConcept C2779338263 @default.
• W2497788249 hasConcept C2780258809 @default.
• W2497788249 hasConcept C2780317896 @default.
• W2497788249 hasConcept C2780962732 @default.
• W2497788249 hasConcept C2781413609 @default.
• W2497788249 hasConcept C526805850 @default.
• W2497788249 hasConcept C71924100 @default.
• W2497788249 hasConcept C90924648 @default.
• W2497788249 hasConceptScore W2497788249C121332964 @default.
• W2497788249 hasConceptScore W2497788249C121608353 @default.
• W2497788249 hasConceptScore W2497788249C126322002 @default.
• W2497788249 hasConceptScore W2497788249C1276947 @default.
• W2497788249 hasConceptScore W2497788249C141071460 @default.
• W2497788249 hasConceptScore W2497788249C150846664 @default.
• W2497788249 hasConceptScore W2497788249C2776694085 @default.
• W2497788249 hasConceptScore W2497788249C2777525834 @default.
• W2497788249 hasConceptScore W2497788249C2778041864 @default.
• W2497788249 hasConceptScore W2497788249C2779338263 @default.
• W2497788249 hasConceptScore W2497788249C2780258809 @default.
• W2497788249 hasConceptScore W2497788249C2780317896 @default.
• W2497788249 hasConceptScore W2497788249C2780962732 @default.
• W2497788249 hasConceptScore W2497788249C2781413609 @default.
• W2497788249 hasConceptScore W2497788249C526805850 @default.
• W2497788249 hasConceptScore W2497788249C71924100 @default.
• W2497788249 hasConceptScore W2497788249C90924648 @default.
• W2497788249 hasIssue "21" @default.
• W2497788249 hasLocation W24977882491 @default.
• W2497788249 hasOpenAccess W2497788249 @default.
• W2497788249 hasPrimaryLocation W24977882491 @default.
• W2497788249 hasRelatedWork W1996550290 @default.
• W2497788249 hasRelatedWork W2028640470 @default.
• W2497788249 hasRelatedWork W2120848645 @default.
• W2497788249 hasRelatedWork W2497788249 @default.
• W2497788249 hasRelatedWork W2569592316 @default.
• W2497788249 hasRelatedWork W2590585323 @default.
• W2497788249 hasRelatedWork W2965534143 @default.
• W2497788249 hasRelatedWork W4245200411 @default.
• W2497788249 hasRelatedWork W940974242 @default.
• W2497788249 hasRelatedWork W2464063248 @default.
• W2497788249 hasVolume "124" @default.
• W2497788249 isParatext "false" @default.
• W2497788249 isRetracted "false" @default.
• W2497788249 magId "2497788249" @default.
• W2497788249 workType "article" @default.